Session » (1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1952

Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series

9:00AM-11:00AM: Abstract Number: 1961

Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome

9:00AM-11:00AM: Abstract Number: 1945

Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals

9:00AM-11:00AM: Abstract Number: 1965

Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 1963

Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis

9:00AM-11:00AM: Abstract Number: 1954

Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center

9:00AM-11:00AM: Abstract Number: 1972

Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial

9:00AM-11:00AM: Abstract Number: 1960

From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence

9:00AM-11:00AM: Abstract Number: 1970

Impaired Health-Related Quality of Life in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Analysis from the COVAD Dataset

9:00AM-11:00AM: Abstract Number: 1967

Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment

9:00AM-11:00AM: Abstract Number: 1966

Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?

9:00AM-11:00AM: Abstract Number: 1953

Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019

9:00AM-11:00AM: Abstract Number: 1969

Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study

9:00AM-11:00AM: Abstract Number: 1971

Muscle Pathology in Patients with Primary Biliary Cholangitis

9:00AM-11:00AM: Abstract Number: 1947

National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England

9:00AM-11:00AM: Abstract Number: 1957

Non-Linear Mendelian Randomization Analyses Support a Role for Low Vitamin D Status in Sarcopenia Risk

9:00AM-11:00AM: Abstract Number: 1964

Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization

9:00AM-11:00AM: Abstract Number: 1968

Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population

9:00AM-11:00AM: Abstract Number: 1959

Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1949

Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1955

Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1956

Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1948

The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1950

Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study

9:00AM-11:00AM: Abstract Number: 1962

Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis

9:00AM-11:00AM: Abstract Number: 1951

Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 1958

Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study

9:00AM-11:00AM: Abstract Number: 1946

Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].